Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography:A pilot study

被引:3
作者
Kazue Shiozawa [1 ]
Manabu Watanabe [1 ]
Yoshinori Kikuchi [1 ]
Takahide Kudo [2 ]
Kenichi Maruyama [2 ]
Yasukiyo Sumino [1 ]
机构
[1] Division of Gastroenterology and Hepatology,Department of Internal Medicine,Toho University Medical Center,Omori Hospital,Tokyo 143-8541,Japan
[2] Department of Clinical Functional Physiology,Toho University Medical Center,Omori Hospital,Tokyo 143-8541,Japan
关键词
Sorafenib; Sonazoid; Contrast-enhanced ultrasonography; Hepatocellular carcinoma; Therapeutic response;
D O I
暂无
中图分类号
R735.7 [肝肿瘤];
学科分类号
100214 ;
摘要
AIM:To determine the usefulness of arrival time parametric imaging(AtPI) using contrast-enhanced ultrasonography(CEUS) with Sonazoid in evaluating early response to sorafenib for hepatocellular carcinoma(HCC).METHODS:Fourteen advanced HCC patients who received sorafenib 400/800 mg/d for at least 4 wk and were followed up by CEUS were enrolled in this study.CEUS was performed before treatment and 2 and 4 wk after treatment,and images of the target lesion in the arterial phase were recorded for each patient.The images were analyzed by AtPI.Color mapping(CM) images obtained by AtPI were compared before and after the treatment.In these CM images,the mean arrival time of the contrast agent in the region of interest from the starting point [mean time(MT)] was calculated.In each patient,differences between MT before and MT 2 and 4 wk after the treatment were compared with responses evaluated 4-8 wk after the treatment by dynamic computed tomography(CT),and statistical analysis was performed.Modified response evaluation criteria in solid tumors was used for the response evaluation.RESULTS:In CM images both 2 and 4 wk after the treatment,delays in the arrival time of the contrast agent were noted in 8 of the 14 patients.In the other 6 patients,no color changes were observed in the tumor,or red and/or yellow increase,suggesting a decrease in blood flow velocity between images 2 and 4 wk after the treatment and those before the treatment.Dynamic CT could be performed 4-8 wk after the treatment in 13 of the 14 patients.Median differences in the MT were 1.13 s and 1.015 s,2 and 4 wk after the treatment,respectively,in the 8 patients who showed stable disease(SD)/partial response(PR) on dynamic CT.Median differences in the MT were-0.39 s and-0.95 s,2 and 4 wk after the treatment,respectively,in the 5 patients who showed progressive disease(PD).Differences in the median MT between SD/PR and PD groups were significant 2 and 4 wk after the treatment with P = 0.019 and P = 0.028,respectively.CONCLUSION:AtPI by CEUS using Sonazoid is suggested to be useful for evaluating early responses to sorafenib.
引用
收藏
页码:5753 / 5758
页数:6
相关论文
共 8 条
[1]   Quantitative functional imaging by Dynamic Contrast Enhanced Ultrasonography (DCE-US) in GIST patients treated with masatinib [J].
Lassau, Nathalie ;
Chami, Linda ;
Koscielny, Serge ;
Chebil, Mohamed ;
Massard, Christophe ;
Benatsou, Baya ;
Bidault, Sophie ;
Cioffi, Angela ;
Blay, Jean-Yves ;
Le Cesne, Axel .
INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) :765-771
[2]   Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma [J].
Lencioni, Riccardo ;
Llovet, Josep M. .
SEMINARS IN LIVER DISEASE, 2010, 30 (01) :52-60
[3]   Parametric imaging using contrast-enhanced ultrasound with Sonazoid for hepatocellular carcinoma [J].
Watanabe, Manabu ;
Shiozawa, Kazue ;
Takahashi, Masayoshi ;
Wakui, Noritaka ;
Otsuka, Yuichiro ;
Kaneko, Hironori ;
Tanikawa, Kayoko ;
Shibuya, Kazutoshi ;
Kamiyama, Naohisa ;
Sumino, Yasukiyo .
JOURNAL OF MEDICAL ULTRASONICS, 2010, 37 (02) :81-86
[4]   Evaluation of the Hemodynamic Status of Focal Hepatic Lesions 20 mm or Less in Diameter by Contrast-Enhanced Ultrasonography Using Sonazoid [J].
Shiozawa, Kazue ;
Watanabe, Manabu ;
Sumino, Yasukiyo .
INTERVIROLOGY, 2009, 52 (04) :213-222
[5]  
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J] . Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao-Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Shenglong Ye,Tsai-Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,Dimitris Voliotis,Zhongzhen Guan. Lancet Oncology . 2009 (1)
[6]   Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models [J].
Chang, Yong S. ;
Adnane, Jalila ;
Trail, Pamela A. ;
Levy, Joan ;
Henderson, Arris ;
Xue, Dahai ;
Bortolon, Elizabeth ;
Ichetovkin, Marina ;
Chen, Charles ;
McNabola, Angela ;
Wilkie, Dean ;
Carter, Christopher A. ;
Taylor, Ian C. A. ;
Lynch, Mark ;
Wilhelm, Scott .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (05) :561-574
[7]  
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasound[J] . Michele Lamuraglia,Bernard Escudier,Linda Chami,Brian Schwartz,Jérome Leclère,Alain Roche,Nathalie Lassau. European Journal of Cancer . 2006 (15)
[8]   Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma [J].
Pang, Roberta ;
Poon, Ronnie T. P. .
CANCER LETTERS, 2006, 242 (02) :151-167